Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 20, 2010

MorphoSys Expands Deal Leveraging Wacker’s Bacterial Secretion Technology

  • MorphoSys and Wacker Chemie expanded their existing collaboration to use Wacker's bacterial secretion technology, Esetec®. MorphoSys will now be able to leverage Esetec for the production of antigen material in addition to the production of antibodies in both the early development phase of therapeutic projects as well as in the production of diagnostic and research antibodies.  

    The Esetec secretion system produces proteins including antibody fragments. The system comprises a specific E. coli strain developed by Wacker that is able to secrete recombinant proteins in their native conformation into the culture medium during fermentation, according to the company. This extracellular production facilitates the purification of recombinant products, and the step of refolding is eliminated. 

    Wacker and MorphoSys first entered into a feasibility study agreement for the use of Esetec for antibody production in 2005. Due to the success of the collaboration, this agreement was supplemented in 2008 with a formal license to use the Wacker technology.


Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »